A p21(Waf1/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3480-3488

  Mutoh, Masato ^a,b   Lung, Feng Di T ^a,c   Long, Ya Qiu ^a   Roller, Peter P ^a   Sikorski, Robert S ^a,d   O'Connor, Patrick M ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TORAY INDUSTRIES INC   (Japan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Medsite Communications   (United States)

^e AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLINE; PEPTIDE; PROTEIN P21;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER INHIBITION; CYTOTOXICITY; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTENNAPEDIA HOMEODOMAIN PROTEIN; BURKITT LYMPHOMA; CELL MEMBRANE; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FLOW CYTOMETRY; HOMEODOMAIN PROTEINS; HUMANS; MICROSCOPY, ELECTRON; MOLECULAR SEQUENCE DATA; NECROSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROLIFERATING CELL NUCLEAR ANTIGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0033565263     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Draetta, G. cdc2 activation: the interplay of cyclin binding and Thr161 phosphorylation. Trends Cell Biol., 3: 287-289, 1993.
2. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
3. 1 cyclin (Cln) function in yeast. Cell, 66: 1197-1206, 1991.
4. 1 arrest. Cell, 76: 1013-1023, 1994.
5. 1. Genes Dev., 7: 812-821, 1993.
6. Van den Heuvel, S., and Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle conlrol. Science (Washington DC), 24: 2050-2054, 1993.
7. Pagano, M., Pepperkok, R., Verde, F., Ansorge, W., and Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J., 11: 961-971, 1992.
8. Dunphy, W. G. The decision to enter mitosis. Trends Cell Biol., 4: 202-207, 1994.
9. Pines, J., and Hunter, T. Cyclin-dependent kinases: an embarrassment of riches? In: C. Hutchison, and D. M. Glover, (eds.), Cell Cycle Control, pp. 144-176. New York: Oxford University Press, 1995.
10. Elledge, S. J., and Harper, J. W. Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 874-878, 1994.
11. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
12. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
13. El-Deiry, W. S., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J., Lin, D., Mercer, W., Kinzler, K., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppressor. Cell, 75: 817-825, 1993.
14. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
15. Xiong, Y., Zhang, H., and Beach, D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell, 71: 505-514, 1992.
16. Zhang, H., Xiong, Y., and Beach, D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell, 4: 897-906, 1993.
17. Gu, Y., Turck, C. W., and Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707-710, 1993.
18. Huppi, T., Siwarski, D., Dosik, J., Michieli, P., Chedid, M., Givol, D., Reed, S., Mock, B., and Mushinski, J. F. Molecular cloning, sequencing, chromosomal localization and expression of mouse p21(Waf1). Oncogene, 9: 3017-3020, 1994.
19. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
20. Cip1/Waf1 proteins following irradiation of human lymphoma cells. Cancer Res., 55: 2387-2393, 1995.
21. 1 checkpoint control. Cell, 82: 675-684, 1995.
22. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
23. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of p21(WAF1/CIP1) by a p53-independem pathway. Cancer Res., 54: 3391-3395, 1994.
24. Jiang, H., Lin, J., Su, Z-Z., Collart, F., Huberman, E., and Fisher, P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21WAF1/ CIP1 expression in the absence of p53. Oncogene, 9: 3397-3407, 1994.
25. Steinman, R. A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D., and El-Houseini, M. E. Induction of p21WAF-1/CIP1 during differentiation. Oncogene, 9: 3389-3396, 1994.
26. Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
27. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Diesseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res., 55: 668-674, 1995.
28. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
29. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
30. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 539-649, 1995.
31. CIP1 Cdk inhibitor family, is a candidate tumor suppresser gene. Genes Dev., 9: 650-662, 1995.
32. Chen, J., Jackson, P. K., Kirschner, M. W., and Dutta, A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (Lond.), 374: 386-388, 1995.
33. Chen, J., Peters, R., Saha, P., Lee, P., Therdore, A., Pagano, M., Wagner, G., and Dutta, A. A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res., 24: 1727-1733, 1996.
34. Cip1. Nature (Lond.), 375: 159-161, 1995.
35. Waf is contained in its N-terminal half ('half-WAF'). Oncogene, 11: 393-395, 1995.
36. Waf-1 gene activities. Mol. Cell. Biol., 16: 1786-1793, 1996.
37. Prelich, G., Kostura, M., Marshak, D. R., Mathews, M. B., and Stillman, B. Cell-cycle regulated proliferating cell nuclear antigen is required for SV40 DNA replication in vitro. Nature (Lond.), 326: 471-475, 1987.
38. Shivji, M. K., Kenny, M. K., and Wood, R. D. Proliferating cell nuclear antigen is required for DNA excision repair. Cell, 69: 367-374, 1992.
39. Flores-Rozas, H., Kelman, Z., Dean, F. B., Pan, Z-Q., Harper, J. W., Elledge, S. J., O'Donnell. M., and Hurwitz, J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase holoenzyme. Proc. Natl. Acad. Sci. USA, 91: 8655-8659, 1994.
40. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-578, 1994.
41. Li, R., Waga, S., Hannon, G. J., Beach, D., and Stillman, B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (Lond.), 371: 534-537, 1994.
42. WAF1/CIP1-/-human cancer cells. Cancer Res., 56: 2250-2255, 1996.
43. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1996.
44. Cip1. Mol. Cell. Biol., 7: 4673-4682, 1996.
45. Adams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., and Kaelin, W. G., Jr. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol., 16: 6623-6633, 1996.
46. WAF1. Curr. Biol., 7: 71-80, 1996.
47. Derossi, D., Joliot, A. H., Chassaing, G., and Prochiantz, A. The third helix of the antennapedia homeodomain translocates through biological membranes, J. Biol. Chem., 269: 10444-10450, 1994.
48. Waf1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res., 57: 1442-1446, 1997.
49. 2 cell cycle arrest in p53-deficient cells. Oncogene, 16: 311-320, 1998.
50. Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogene, 12: 595-607, 1996.
51. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
52. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L-H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., Swindell, E., Fox, M. P., and Wei, N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
53. Waf1/Cip1 complexed with human PCNA. Cell, 87: 297-306, 1996.
54. Simmons, C. G., Pitts, A. E., Mayfield, L. D., Shay, J. W., and Corey, D. R. Synthesis and membrane permeability of PNA-peptide conjugates. Bioorg. & Med. Chem. Lett., 7: 3001-3006, 1997.
55. Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry, 27: 1-20, 1997.
56. Dive, C., Gregory, C. D., Phipps, D. J., Evans, D. L., Milner, A. E., and Wyllie, A. H. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim. Biophys. Acta, 1133: 275-285, 1992.
57. Pan, Z-Q., Reardon, J. T., Li, L., Flores-Rozas, H., Legerski, R., Sancar, A., and Hurwitz, J. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J. Biol. Chem., 270: 22008-22016, 1995.
58. Waf1 and proliferating cell nuclear antigen. Curr. Biol., 5: 275-282, 1995.
59. Cip1/Waf1 protein with overlapping peptide segments. In: R. Ramage and R. Epton (eds.), Peptides 1996, pp. 601-602. Kingwinford, England: Mayflower Sci. Pub., 1998.
60. Kip1 cydin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (Lond.), 382: 325-331, 1996.
61. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
62. 1 arrest with induction of cyclin-dependent kinase CDK2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
63. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M. Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998.
64. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
65. waf1/cip1 protein associates with detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites. Oncogene, 13: 1591-1598, 1996.
66. WAF1. Science (Washington DC), 277: 1996-2000, 1997.